Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

2articles mentioning drugs

11drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: STK-012 ×

STK-012

This drug is selected. Its supporting articles are shown below.

Articles mentioning STK-012

2 articles · page 1 of 1

1345 Initial phase 1a/1b results of STK-012, an α/β IL-2 receptor biased partial agonist, with pembrolizumab, pemetrexed, and carboplatin in 1L PD-L1 negative non-squamous NSCLC

jitc · abstract · 2025-11-07 · 7 matching annotations

95.9%

STK-012 pembrolizumab carboplatin pemetrexed STK-012-101 Cemiplimab 1L NSQ NSCLC Dana Farber Cancer Institute

… with treatment-naïve, stage IV NSQ NSCLC without AGAs received STK-012 subcutaneously (SC) Q3W + standard of care pembrolizumab, pemet…

682 STK-012, a first-in-class α/β IL-2 receptor biased partial agonist enhances the anti-tumor efficacy of bispecific antibodies

jitc · abstract · 2025-11-04 · 4 matching annotations

97.0%

STK-012 pembrolizumab mSTK-012 cancer NCT05098132 Non-small cell lung cancer NSCLC

…mab and chemotherapy. These findings highlight the potential of STK-012 to overcome key limitations of the next wave immunotherapies by…